Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCQ908 in Severe Hypertriglyceridemia and Chylomicronemia
NCT01146522Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2010
- Primary completion
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in familial lipoprotein lipase deficiency (LPLD), hyperlipoproteinemia type V, hypertriglyceridemia and 1 more comparing LCQ908 Arm with Placebo Arm (2 arms). Primary endpoint: Fasting and postprandial plasma triglycerides at 3 weeks. Started May 2010; status: completed.
02
Drugs
pradigastat
03
Conditions
familial lipoprotein lipase deficiency (LPLD)hyperlipoproteinemia type Vhypertriglyceridemiafamilial chylomicronemia syndrome (FCS)
Beyond the preview
Go deeper on NCT01146522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01146522.